• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » U.S. Clinical Trials Taking Longer Despite FDA Efforts to Accelerate Drug Development

U.S. Clinical Trials Taking Longer Despite FDA Efforts to Accelerate Drug Development

July 20, 2020

The average time needed to complete clinical development of a new drug in the U.S. is increasing, outpacing the FDA’s efforts to accelerate drug approval and lengthening the overall amount of time needed to bring a new drug to market, according to a new report.

The average combined clinical trial and approval timeline increased by almost five months between 2008 and 2018, an analysis by the Tufts Center for the Study of Drug Development (CSDD) shows. At the same time, the clinical trial timeline grew by nearly seven months, while the approval phase dropped by nearly two months.

Drugs that fell under the FDA’s expedited review program, however, were brought to market 11 percent faster than those without expedited review. And the trial-to-approval timeline for orphan drugs decreased 12 percent.

The duration of clinical trials increased across all phases, the study shows, with the greatest increase (9.2 percent) in phase 2.

To read a summary of the results, click here: https://bit.ly/32t9vj7.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing